Physician profile
Eric C Burdge
NPI 1851381339
$3,471.27
in general payments reported to CMS, 2019-2025
11 companies · $2,227 in 2025
The $2,227 reported for 2025 was more than what 83% of Surgical Oncology providers received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $187 · 2020: $472 · 2021: $327 · 2022: $14.13 · 2023: $173 · 2024: $72.06 · 2025: $2,227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,753 · Food and Beverage: $718.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,752.80 |
| Food and Beverage | $718.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axogen | $2,194.21 | 2025 | |
| Vector Surgical, LLC | $600.00 | 2020-2021 | |
| Myriad Genetic Laboratories, INC. | $227.32 | 2021-2025 | Myrisk |
| Amgen INC. | $160.42 | 2019-2020 | |
| Genentech USA, INC. | $110.70 | 2019 | |
| Merck Sharp & Dohme LLC | $60.88 | 2023-2024 | Lynparza, Keytruda |
| Novo Nordisk INC | $44.22 | 2019 | |
| Medtronic, INC. | $29.70 | 2023 | Plasmablade(Tm) |
| Merit Medical Systems INC | $17.27 | 2020 | |
| Smith+Nephew, INC. | $13.50 | 2019 | |
| Tactile Systems Technology INC | $13.05 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Burdge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.